Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 5/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SELP | P16109 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258406 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL11051906 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL11228741 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL258662 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL6856630 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL10882190 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL233312 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL258527 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL21274180 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL31510848 | 1.00 | CASP2 (0.61) | CASP2FAAHNAAADNM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3554263-B1 | COMPOSITIONS AND METHODS THAT MODULATE DIGESTIBILITY IN A COMPANION ANIMAL | NESTLE SA (CH) | 2023-07-19 | — | — | EP | claimed |
| CN-116413427-A | Screening method and application of echinococcosis early diagnosis marker based on metabonomics | 新疆农业大学 | 2023-07-11 | — | — | CN | claimed |
| EP-3805756-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2021-04-14 | — | — | EP | claimed |
| CN-106537145-B | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | 麦特博隆股份有限公司 | 2020-08-25 | — | — | CN | claimed |
| CN-109414038-A | Compositions and methods for modulating digestibility in companion animals | 雀巢产品技术援助有限公司 | 2019-03-01 | — | — | CN | claimed |
| US-20180275144-A1 | DIAGNOSTIC TOOLS FOR ALZHEIMER'S DISEASE | PHARNEXT (FR) | 2018-09-27 | — | — | US | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2016124574-A1 | DIAGNOSTIC TOOLS FOR ALZHEIMER'S DISEASE | PHARNEXT (FR) | 2016-08-11 | — | — | WO | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-12559611-B2 | Hydrophobic alginic acid particle group and method for producing same | NISSHINBO HOLDINGS INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20260043065-A1 | Methods of Administering 3,4-Diaminopyridine | SERB SA (BE) | 2026-02-12 | — | — | US | disclosed |
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | disclosed |
| US-12491217-B2 | Compositions and methods for promoting healthy neural development in an unborn baby | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-09 | — | — | US | disclosed |
| EP-0267726-A2 | Coreshell particle dispersions | ROHM AND HAAS COMPANY (US) | 1988-05-18 | — | — | EP | disclosed |
| US-4677003-A | POLYMERS/SHELL-CORE | ROHM AND HAAS COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0187505-A2 | Methods of making latex polymer compositions, latex polymer compositions and uses thereof | ROHM AND HAAS COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
| EP-0016518-B1 | AMBIENT OR LOW-TEMPERATURE CURABLE COATING COMPOSITIONS FOR COATING RIGID SUBSTRATES | ROHM AND HAAS COMPANY (US) | 1984-05-16 | — | — | EP | disclosed |
| US-4256809-A | CURED WITH A DICARBOXYLIC ACID BIS-HYDRAZIDE OR BIS-HYDRAZONE | ROHM AND HAAS COMPANY (US) | 1981-03-17 | — | — | US | disclosed |
| US-4210565-A | COPOLYMERS OF ACRYLIC ALDEHYDES CURED WITH BIS- HYDRAZIDES OR HYDRAZONES | ROHM AND HAAS COMPANY (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | CYP27A1, LIPC, CYP46A1 | CASP2 4358/4885FAAH 1529/4885NAAA 1367/4885 |
| US-20260043065-A1 | Methods of Administering 3,4-Diaminopyridine | NAT1, SAT1, NANS | CASP2 3117/4885FAAH 2280/4885NAAA 318/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | CASP2 3492/4885FAAH 384/4885NAAA 584/4885 |
| US-12559611-B2 | Hydrophobic alginic acid particle group and method for producing same | ALG3, ALG1, HACD3 | CASP2 3030/4885FAAH 2324/4885NAAA 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.